There are about 3468 clinical studies being (or have been) conducted in Singapore. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The aims of the research are to develop an age-appropriate and culturally sensitive older person-centered, Singapore-contextualized Dance-based Exergame (SinDance), and to pilot test its effectiveness in improving physical function and activity daily living (ADL) and reducing depressive symptoms and falls among community-dwelling older people. It is hypothesized that participants in the SinDance will have: (1) improved postural balance, muscle strength, and ADL; and (2) reduced depressive symptoms, fear of falling, and number of falls, compared to those in the control group. The research will be structured as a two-phase study. 1. In Phase one, development of the SinDance system will be undertaken. 2. In Phase two, a pilot randomized control trial will be conducted to evaluate the feasibility and potential effectiveness of the newly developed SinDance exergame on the proposed outcomes. - Eligible participants will be recruited from Lions Befrienders (LB) senior activity centre and randomly assigned to the SinDance group or the control group. - Participants in the intervention group will receive one face-to-face briefing session and will be required to participate in the newly developed SinDance exergame 3 times a week for 6 weeks, while those in the control group will attend usual activities provided by the centers. - Outcomes will be measured at baseline, immediate after intervention, and 3 months from baseline.
Ingested beetroot contains inorganic nitrate which is later converted to nitric oxide (NO) in the bloodstream. NO is an important signaling molecule with several physiological functions in the body including acting as a vasodilator, expanding arteries and improving blood flow. Beetroot juice contain inorganic nitrate and consumption of beetroot has been shown to improve skeletal muscle contractility and metabolism enhancing high-intensity exercise performance. Isotonic sports drinks contain carbohydrates and sodium, which also improve exercise performance by providing exogenous glucose for energy to the working muscle and central nervous system and enabling faster absorption of fluid into the bloodstream. The ingestion of exogenous nitrate and isotonic-carbohydrate drink are recognized strategies for promoting exercise performance but whether they can be effectively combined has not been shown. This study will compare the salivary nitrite response, muscle oxygenation and time-trial performance after ingestion of two isotonic drinks with high in nitrate or with no nitrate.
The study aims to look at the blood flow restriction (BFR) + high intensity interval training (HIIT) variables to induce an optimal acute training stimulus (i.e., acute responses in main outcome measures of muscular activation, muscular deoxygenation, and secondary outcome measures of heart rate (HR), blood lactate (bLa), subjective ratings of perceived exertion and discomfort) The hypotheses for this study are: (i) BFR increases muscular deoxygenation, muscular activation when HIIT exercise is of the same intensity, (ii) however, comparing between a lower BFR + HIIT exercise intensity (e.g. 80% V̇O2max) and higher HIIT exercise intensity (e.g. 100% V̇O2max), muscular deoxygenation and activation will be similar but HR will be lower in the BFR + HIIT condition.
The purpose of the study is to use the polarization sensitive optical coherence tomography (PS-OCT) developed by Singapore Eye Research Institute, to evaluate the potential OCT scleral biomarkers capable of predicting risk of myopia progression.
The current study aims to investigate the cognitive effects of diet-induced blood glucose fluctuations on cognitive performance in healthy older adults over multiple days, taking advantage of the currently available techniques to continuously measure blood glucose levels and to assess cognitive performance in a real-life setting. In this fully decentralized study, subjects will undergo two times a three-day measurement period, where their blood glucose will be continuously measured by a minimally invasive sensor and where the cognitive performance is measured at multiple time points throughout a day using a short test battery administered on their mobile phone. In addition to receiving standardized breakfast and lunch meals, the subjects are administered a low-GI(Glycemic Index) or normal-GI(Glycemic Index) snack in the morning and afternoon.
The main purpose of this study is to conduct blood tests to measure how much LY3493269 is in the bloodstream and how the body handles and eliminates LY3493269 when administered orally as test compared to reference formulations in healthy participants in fed and/or fasted states. The study will also evaluate the safety and tolerability of LY3493269 in these participants. The study will last up to 43 days excluding the screening period.
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either BRII-196/BRII-198 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H3.
This study looks at the safety and effectiveness of VIR-7831 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either VIR-7831 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H2.
This study looks at the safety and effectiveness of LY3819253 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either LY3819253 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H1.